Propofol post-conditioning protects the blood brain barrier by decreasing matrix metalloproteinase-9 and aquaporin-4 expression and improves the neurobehavioral outcome in a rat model of focal cerebral ischemia-reperfusion injury

FENG-TAO JI+, JIAN-JUN LIANG+, LI-PING MIAO, QIANG WU and MING-HUI CAO

Department of Anesthesiology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China

Received February 15, 2014; Accepted November 3, 2014

DOI: 10.3892/mmr.2015.3585

Abstract. Propofol, an intravenous anesthetic, inhibits neuronal apoptosis induced by ischemic stroke, protects the brain from ischemia/reperfusion injury and improves neuronal function. However, whether propofol is able to protect the blood brain barrier (BBB) and the underlying mechanisms have remained to be elucidated. In the present study, a rat model of cerebral ischemia/reperfusion was established, using a thread embolism to achieve middle cerebral artery occlusion. Rats were treated with propofol (propofol post-conditioning) or physiological saline (control) administered by intravenous injection 30 min following reperfusion. Twenty-four hours following reperfusion, neurobehavioral manifestations were assessed. The levels of cephaloedema, damage to the BBB and expression levels of matrix metalloproteinase-9 (MMP-9), aquaporin-4 (AQP-4) and phosphorylated c-Jun N-terminal kinase (pJNK) were determined in order to evaluate the effects of propofol on the BBB. In comparison to the cerebral ischemia/reperfusion group, the levels of brain water content and Evans blue content, as well as the expression levels of MMP-9, AQP-4 and pJNK were significantly reduced in the propofol post-conditioning group. These results indicated that propofol post-conditioning improved the neurobehavioral manifestations and attenuated the BBB damage and cephaloedema induced following cerebral ischemia/reperfusion. This effect may be due to the inhibition of MMP-9 and AQP-4 expression, and the concurrent decrease in JNK phosphorylation.

Introduction
Reperfusion of ischemic brain tissues is an effective protocol for the treatment of stroke. However, the aggravation of ischemia and hypoxia as well as the necrosis/apoptosis of neurons in the peripheral zone destroys the normal structure and function of brain tissues (1). The underlying mechanism of this effect involves the release of oxygen free radicals and excitatory amino acids as well as the activation of apoptosis-associated genes (including an increase in the expression of pro-apoptotic and a decrease in anti-apoptotic genes) (1). The destruction of the blood brain barrier (BBB) further induces cerebral edema and normal brain-tissue damage. These effects have markedly influenced the efficacy of therapies for cerebral ischemia/reperfusion injury (2). Numerous studies have shown that during cerebral ischemia in the BBB, matrix metalloproteinase-9 (MMP-9) and aquaporin-4 (AQP-4) have crucial roles (3,4) in the development of cerebral edema. MMP-9 is able to degrade the extracellular matrix and BBB, influence the permeability of blood vessels and participate in the induction of vasogenic brain edema (3). AQP-4 regulates water metabolism, water distribution and osmotic pressure (4). Furthermore, the c-Jun N-terminal kinase (JNK) pathway is involved in the activation of MMP-9 and AQP-4 (5,6).

Propofol, which is clinically used as an anesthetic, reduces cerebral blood flow, oxygen consumption and intracranial pressure (7). A previous study has indicated that propofol pre- and post-conditioning treatments may protect tissues from cerebral ischemia-reperfusion injury. Propofol inhibits the activation of proapoptotic genes, thereby reducing neuronal apoptosis and improving prognosis (7-9). However, previous studies have focused on the protective effects of propofol on neurons and the mechanisms underlying these effects, whereas there are few studies regarding the effects of propofol on the BBB and its underlying mechanisms. To the best of our knowledge, no study has been performed investigating the effects of propofol on the expression of MMP-9, AQP-4 and phosphorylated JNK following cerebral ischemia/reperfusion.

In the present study, an established rat model of cerebral ischemia/reperfusion was treated with propofol administered via intravenous injection. The condition of the BBB, level of...
cephaloedema and neural functions of propofol-treated rats were assessed and scored to evaluate the protective effects of propofol post-conditioning. The expression levels of MMP-9 and AQP-4 and the phosphorylation level of pJNK were also determined in order to elucidate the mechanism underlying the protective effects of propofol on the BBB.

Materials and methods

Drugs and reagents. The drugs and reagents used in the present study included propofol (Diprivan; AstraZeneca, London, UK), Evans blue (EB) and dimethylformamide (Sigma-Aldrich, St. Louis, MO, USA). Antibodies included rabbit anti-mouse MMP-9 polyclonal antibody and JNK/pJNK polyclonal antibody (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) rabbit anti-mouse AQP-4 antibody (Chemicon®, EMD Millipore, Billerica, MA, USA) and rabbit anti-mouse β-actin antibody (Sigma-Aldrich). A western blotting kit was purchased from KPL (Gaithersburg, MD, USA).

Experimental animal selection and grouping. Ninety-six healthy adult Wistar rats, weighing 260-300 g and aged 4-6 weeks (Experimental Animal Centre of Zhongshan University, Guangzhou, China) were kept in a 12 h/12 h light/dark cycle at 28-32˚C with free access to food and water. Rats were randomly divided into four groups: The sham operation group (group S, n=24), the ischemia reperfusion group (group I, n=24) and two propofol-treated groups, which included group P1 (20 mg/kg/h propofol, n=24) and group P2 (40 mg/kg/h propofol, n=24). The study was approved by the Animal Care Committee of Sun Yat-sen University (Guangzhou, China) and performed in strict accordance with the National Institutes of Health Guide for the Use of Laboratory Animals.

Preparation of cerebral ischemia/reperfusion rat model and assessment of neural function. The rats were subjected to fasting without drinking for 12 h prior to surgery. Anesthesia was induced in a Plexiglass chamber with 4% halothane (Sigma-Aldrich), followed by tracheal intubation and mechanical ventilation with 1.3% halothane in 30% O₂/70% N₂O. The left femoral artery was cannulated to monitor blood pressure and spontaneous breath was conserved. The rat was prepared for surgery by the removal of hair in the middle of the neck in the supine position. Subsequently the skin was prepared with 75% alcohol and a surgical incision was made at the supine position. Subsequently the skin was prepared with 75% alcohol and a surgical incision was made at the supine position. Subsequently the skin was prepared with 75% alcohol and a surgical incision was made at the supine position.

Drug treatment. The P1 and P2 groups were treated with 20 mg/kg/h or 40 mg/kg/h propofol, respectively, for 30 min via the tail vein, 30 min following reperfusion. Group I was treated with an equal amount of physiological saline (Sigma-Aldrich) and in group S, the incision was made but no arterial occlusion was performed.

Detection of EB. The permeability of the BBB was determined according to the protocol described by Uyama et al (12), by the detection of EB fluorescence. Twenty-three hours following reperfusion, rats were anesthetized with 10% chloral hydrate and 2% EB (3 ml/kg) was injected into the femoral vein. One hour later, the ventriculus sinister was washed with physiological saline for 0.5 h. The brain was removed by decollation and surface moisture was blotted with filter paper. The cerebral cortex of the ischemic side was excised and the wet weight was measured with an electronic balance prior to incubation with 4 ml dimethylformamide (Sigma-Aldrich) at 50˚C for 4 h followed by centrifugation at 1509 x g for 15 min. The absorbency of the supernatant at 620 nm was determined using a Hitachi U2001 (Hitachi, Ltd, Tokyo, Japan). The content of EB (µg/g) was subsequently calculated according to the standard curve method (12).

Immunohistochemical examination. Half of the animals in each group were randomly selected to be sacrificed by administration of 5% halothane (Sigma-Aldrich) and fixed in the dorsal position immediately following behavioral testing. The rat hearts were exposed by opening the chest from the xiphisternum and were perfused through the ascending aorta with 150 ml saline followed by 400 ml 4% paraformaldehyde. Following perfusion, the brain was removed, fixed in 4% paraformaldehyde (Sigma-Aldrich) overnight and subsequently transferred to 30% sucrose (Sigma-Aldrich) and incubated for 3-5 days. The damaged brain area was dissected into 1-mm coronal sections. Sequential 10-µm coronal sections were cut from the sections (from bregma -2.3 to -2.45 mm) by cryomicrotomy (CM1900; Leica Microsystems GmbH, Wetzlar, Germany), the sections were treated with 0.3% H₂O₂ (Sigma-Aldrich) in methanol for 30 min, hydrated gradually in distilled water and incubated for 2 h with 5% goat serum (Sigma-Aldrich) to block nonspecific immune reactions. The sections were subsequently incubated at 4˚C overnight with rabbit polyclonal anti-MMP-9 or anti-AQP-4 antibodies (1:2,000). Following washing with Tris-buffered saline (Sigma-Aldrich), the sections were incubated with biotinylated goat anti-rabbit immunoglobulin G (IgG) (1:200; Zhongshan Golden Bridge Biotechnology Co., Ltd, Beijing, China) for 2 h.
followed by incubation with avidin-biotinperoxidase complex (1:200; Zhongshan Golden Bridge Biotechnology Co.) for 2 h. Finally, the sections were exposed to 0.01% 3,3-diaminobenzidine (Sigma-Aldrich) for 0.5-2 min, followed by examination under a light microscope (Olympus BX51; Olympus Corp., Tokyo, Japan). The optical density of MMP-9 and AQP-4 immunoreactivity was evaluated in an area of 1x1 mm² in the boundary zone.

Western blot analysis. Twenty-four hours following reperfusion, rats were sacrificed. The brains were removed and immediately cut into two 2-mm sections on dry ice, excluding 4 mm of the rostral tissue. Slices were cut into the right and left hemispheres, and the right striatum and parietal cortex were isolated and homogenized in tissue lysate buffer (10 ml/mg tissue) containing a mixture of proteinase inhibitors (Thermo Fisher Scientific China Co., Ltd, Beijing, China), prior to dispersion by sonication. The homogenate was centrifuged at 2,250 x g for 30 min at 4°C, and the supernatant was saved. A bicinchoninic acid assay (Pierce Biotechnology, Inc.; Thermos Scientific, Waltham, MA, USA) for 1 min, and exposure onto nitrocellulose filters were separated on using 10% SDS-PAGE and transferred to nitrocellulose membranes (Sigma-Aldrich) at 100 mV. The membranes were blocked with 5% non-fat milk (Sigma-Aldrich) in phosphate-buffered saline with 0.1% Tween-20 (Sigma-Aldrich) for 1 h at room temperature and incubated overnight at 4°C with rabbit anti-mouse MMP-9 polyclonal antibody (1:2,000; Santa Cruz Biotechnology, Inc.), rabbit anti-mouse AQP-4 antibody (1:2,000; Abcam, Cambridge, MA, USA) or rabbit polyclonal anti-pJNK antibody (1:2,000; Santa Cruz Biotechnology, Inc.). Following three washes in Tris-buffered saline for 5 min, the blots were incubated for 1 h at room temperature with the appropriate horseradish peroxidase-conjugated secondary antibody (1:3,000; Santa Cruz Biotechnology, Inc.). MMP-9, AQP-4 and pJNK were subsequently visualized by incubation with enhanced chemiluminescence reagent (Thermo Fisher Scientific, Waltham, MA, USA) for 1 min, and exposure onto hyperfilm (Sigma-Aldrich) for 1-10 min. Membranes which were positive for JNK were re-blocked with 5% non-fat milk for 1 h at room temperature and incubated with rabbit polyclonal anti-JNK antibody (Santa Cruz Biotechnology, Inc.) overnight at 4°C. Visualization of JNK was performed as described above. Image J 1.35 software (National Institutes of Health, Bethesda, MD, USA) was used to analyze the relative density values.

Table I. Effect of propofol post-conditioning on neurobehavioral scores, water content and EB content 24 h following reperfusion.

<table>
<thead>
<tr>
<th>Group</th>
<th>Neurobehavioral scores [M( Q ), n=18]</th>
<th>Water content (%) , n=6</th>
<th>EB content (µg/g, n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S</td>
<td>0</td>
<td>77.41±0.19</td>
<td>0.54±0.31</td>
</tr>
<tr>
<td>I</td>
<td>3.0 (1.0)</td>
<td>86.51±0.53</td>
<td>12.65±3.14</td>
</tr>
<tr>
<td>P1</td>
<td>2.0 (1.0)</td>
<td>82.72±0.86</td>
<td>5.72±2.78</td>
</tr>
<tr>
<td>P2</td>
<td>2.0 (0.5)</td>
<td>81.25±0.67</td>
<td>4.76±2.17</td>
</tr>
</tbody>
</table>

Statistical analysis. Data were analyzed using SPSS 16.0 (SPSS, Inc., Chicago, IL, USA). Values are expressed as the mean ± standard deviation. Differences between groups were analyzed using one-way analysis of variance and multiple comparisons were made using the least significant difference test. Data of skewed distribution are presented as the median. P<0.05 was considered to indicate a statistically significant difference between values.

Results

Propofol post-conditioning improves neurobehavioral scores and decreases water- and EB content 24 h following reperfusion. The assessment of neurological function indicated that all experimental animals exhibited post-ischemic neurological deficits. Rats in groups I, P1, and P2 scored significantly higher than those in group S (P<0.05). Compared with the rats in group I, those in groups P1 and P2 scored significantly lower (P<0.05). The experimental groups demonstrated higher water content and EB content in the ischemic hemisphere in comparison to that of group S (P<0.05). The water and EB content were significantly reduced in groups P1 and P2 compared to those in group I (P<0.05; Table I).

MMP-9 and AQP-4 expression in the ischemic hemisphere are attenuated following propofol treatment. Immunohistochemical analysis indicated that the expression levels of MMP-9 and AQP-4 in ischemic brain tissue in group I were significantly increased compared to those in group S (P<0.05). Following propofol post-conditioning, the expression levels of MMP-9 and AQP-4 were significantly decreased in groups P1 and P2 compared with those in group I (P<0.05), although expression levels remained significantly higher than those in group S (P<0.05; Figs. 1 and 2).

Propofol post-conditioning decreases the expression of MMP-9, AQP-4 and pJNK in brain tissues. Twenty-four hours following ischemia/reperfusion, the expression levels of MMP-9, AQP-4 and the levels of pJNK were significantly increased. Following treatment with propofol, the expression levels of MMP-9, AQP-4 and pJNK in groups P1 and P2 were significantly decreased (P<0.05). Furthermore, the expression levels of MMP-9, AQP-4 and pJNK were significantly decreased in group P2 compared with those in group P1 (P<0.05; Figs. 3-5).
Discussion

The middle cerebral artery is prone to ischemic cerebrovascular disease. In a previous study, a model of cerebral ischemia/reperfusion was established using the Longa method (11), which was selected for the high success rate, reproducibility and low risk of complications. This established model effectively simulated the clinical and pathological characteristics of cerebral infarction. In the present study, rats with cerebral ischemia/reperfusion scored significantly lower in the assessment of neural function. Cerebral infarction was observed in the ischemic hemisphere, which indicated that the model reflected the clinical and pathological characteristics of cerebral infarction. Vascular occlusion resulted in cerebral circulatory dysfunction, and therefore cerebral ischemia and hypoxia irreversibly damaged neurons in the affected
part of the brain. Furthermore, damage to the BBB induced successive cerebral edema, which further impaired brain tissues. A significant improvement in neural function was observed following propofol post-conditioning in cerebral ischemia/reperfusion rats and the water content of the brain was also decreased. These results demonstrated that propofol treatment may protect against cerebral ischemia/reperfusion damage, which was in agreement with the results reported in a previous paper (9).

The aquaporins are a family of water-selective cell membrane transporters. AQP-4 widely exists in the central nervous system, and localizes to the membrane of astrocytes, subarachnoid space, glial cells surrounding vessels, ependymal cells and the choroid plexus (13). AQP-4 is a critical component of integrated water and potassium homeostasis (14), and has important roles in water metabolism, localization and osmotic pressure (4). AQP-4 knock-out rats were found to have improved cephaloe德ma following cerebral ischemic stroke (15). MMP-9 is a type of matrix metalloproteinase that is able to degrade the basal lamina and disrupt the BBB. MMP-9 is involved in the pathophysiological process of cerebral ischemia via the degradation of tight junctions between the basal lamina and endothelial cells, which results in the destruction of the BBB (16). MMP-9 has a pivotal role in BBB proteolysis (17), and increased MMP-9 expression and activation increases the permeability of the BBB and may therefore exacerbate cephaloedema (3,18,19). Furthermore, during cerebral ischemia hypoxia-inducible factor-1α may damage the BBB by activating the expression of AQP-4 and MMP-9 and aggravating cerebral edema. Inhibitors of AQP-4 and MMP-9 may protect the BBB to a certain extent (20). The extent of brain edema observed in cerebral ischemia/reperfusion animals was significantly reduced following inhibition, and the animals demonstrated an improved prognosis (21-23). These results indicated that the mechanism underlying BBB protection may be associated with the inhibition of AQP-4 and MMP-9 function. Studies have additionally demonstrated that propofol inhibited the expression of AQP-4 in astroglia in vitro (23) and decreased the expression of MMP-9 in vivo (24). In the present study, the expression levels of AQP-4 and MMP-9 were markedly lower in groups P1 and P2 than those in group S, indicating that treatment with propofol inhibited the expression of these proteins.
The activity of AQP-4 and MMP-9 is influenced by numerous factors. Studies have indicated that damage to the central nervous system may activate the expression of MMP-9 and AQP-4 via the JNK pathway (5,6). JNK is a member of the mitogen-activated protein kinase (MAPK) family, which are involved in mediating the inflammatory response following cerebral ischemia, cell factors, cell proliferation and differentiation as well as the process of oxidant stress (5,6). The activation of JNK induces the phosphorylation of downstream factors, including c-Jun, protein 53 and activator protein 1, as well as modulating gene expression, protein synthesis and neuronal apoptosis (25-28). Animal experiments have revealed that the phosphorylation of JNK is involved in neuronal apoptosis, and that the inhibition of JNK phosphorylation is beneficial for reducing the infarct area and improving prognosis following cerebral ischemia (29). In vitro experiments demonstrated that propofol inhibited the activation of JNK and reduced the levels of cell death induced by oxidative stress (30). Previous studies demonstrated that intraperitoneal administration of 150 mg/kg propofol or intravenous administration of 20 mg/kg propofol significantly alleviated cerebral edema, decreased the infarct size during ischemia/reperfusion injury and improved the National Institutes of Health Stroke Scale (NIHSS) score in a rat model (9). Therefore, the dosage of propofol selected for use in the present study was reasonable and effective in accordance with previous experiments. The results of the present study indicated that the levels of pJNK in groups P1 and P2 were markedly lower than those in the ischemia/reperfusion group. Due to their similar chemical structures, propofol has analogous biochemical functions to those of Vitamin E, including anti-oxidative, mitochondrial protective and free-radical scavenging activity (31-33). Furthermore, propofol inhibits the phosphorylation of JNK (30,34). These results therefore indicated that the mechanism underlying the inhibitory effect of propofol on AQP-4 and MMP-9 may be via inactivation of the JNK pathway.

The function of the BBB is to maintain the central nervous system and following ischemia/reperfusion, the structure and function of the BBB is altered. When the BBB is damaged, its permeability is increased, which allows factors that cannot cross the barrier under physiological conditions to cross the BBB (2). This process may induce or aggravate cephaloedema. The increased permeability of the BBB will additionally further increase leukocyte infiltration in the ischemic brain tissue, enhancing inflammation (35). EB is a classical indicator of BBB permeability (12). The complex of EB and plasma albumin (ESA) is unable to cross the BBB under normal conditions; however, when the BBB is damaged, ESA is able to invade and stain the brain. The infiltration of EB across the BBB is positively correlated with the extent of BBB destruction (12). Propofol decreased the expression of AQP-4 and MMP-9 in ischemia/reperfusion rats and down-regulated the phosphorylation of JNK, therefore protecting the integrity of the BBB. The lower water content of groups P1 and P2 compared with that of group I indicated that propofol treatment may protect the brain by reducing the damage to the BBB and the extent of cephaloedema.

Propofol reduced the levels of cephaloedema and the destruction of the BBB following ischemia/reperfusion and improved the score on the NIHSS. The underlying mechanism involved the inhibition of AQP-4, MMP-9 and phosphorylation of JNK. In conclusion, the results of the present study indicated that propofol exerts a neuroprotective effect via protection of the BBB.

Acknowledgements

The present study was supported by the Guangdong Province Science and Technology Plan Project, Guangzhou, China (no. 2010B080701004) and the Guangdong Province Medical Research Fund (no. B2010092).

References


